| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Agios Pharmaceuticals, Inc. (AGIO) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 22 sells. AGIO is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 149.1K | $5.23M | - | |
| Other | 67.7K | $2.38M | - | |
| CFO | 40.3K | $1.42M | - | |
| Other | 34.6K | $1.22M | - | |
| Dir | 17.8K | $624.9K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2019 | Biller Scott | Chief Scientific Officer | Sale+OE | 9,000 | $65.00 | $585,000.00 | -25.3% | |
| Nov 5, 2018 | Biller Scott | Chief Scientific Officer | Sale+OE | 3,000 | $69.69 | $209,071.00 | -1.9% | |
| Oct 5, 2018 | Biller Scott | Chief Scientific Officer | Sale+OE | 3,000 | $69.79 | $209,377.30 | -1.4% | |
| Sep 28, 2018 | Alenson Carman65 | Principal Accounting Officer | Sale+OE | 152 | $76.45 | $11,620.40 | -100% | |
| Sep 12, 2018 | Maraganore John | Director | Sell | 27,717 | $72.23 | $2,002,110.48 | -22.2% | |
| Sep 5, 2018 | Alenson Carman65 | Principal Accounting Officer | Sale+OE | 312 | $83.00 | $25,896.00 | -67.2% | |
| Sep 5, 2018 | Biller Scott | Chief Scientific Officer | Sale+OE | 3,000 | $83.07 | $249,215.00 | -1.7% | |
| Aug 30, 2018 | Bowden Christopher82 | Chief Medical Officer | Sale+OE | 2,000 | $80.03 | $160,051.00 | -52.0% | |
| Aug 24, 2018 | Hoerter Steven L. | Chief Commercial Officer | Sale+OE | 2,050 | $74.92 | $153,586.00 | -100% | |
| Aug 6, 2018 | Biller Scott | Chief Scientific Officer | Sale+OE | 3,000 | $80.11 | $240,333.00 | -1.7% |